Edition:
United States

Reckitt Benckiser Group PLC (RB.L)

RB.L on London Stock Exchange

6,317.00GBp
12:06pm EDT
Change (% chg)

159.00 (+2.58%)
Prev Close
6,158.00
Open
6,142.00
Day's High
6,336.00
Day's Low
6,142.00
Volume
1,194,255
Avg. Vol
1,794,153
52-wk High
8,000.00
52-wk Low
5,255.00

Select another date:

Wed, May 16 2018

BRIEF-Aspen's Infant Formula Unit Is Said To Draw Reckitt, Perrigo - Bloomberg

* ASPEN'S INFANT FORMULA UNIT IS SAID TO DRAW RECKITT, PERRIGO - BLOOMBERG, CITING SOURCES

Reckitt takes hit from stumbling Scholl and price pressure

LONDON Reckitt Benckiser lagged other consumer good makers in the first quarter as further falls in Scholl footcare and lower prices hit the British company's sales growth.

UPDATE 3-Reckitt takes hit from stumbling Scholl and price pressure

* Shares down as much as 6 pct to 3-year-low (Adds CEO comments)

BRIEF-Reckitt Benckiser Q1 Revenue Up 23 Pct at 3.11 Bln Stg

* ON TRACK FOR FULL YEAR NET REVENUE TARGET OF +13-14% (TOTAL CONSTANT), IMPLYING +2%-3% LFL

Britain's Reckitt Q1 sales growth misses estimates

LONDON, April 20 British consumer goods maker Reckitt Benckiser reported lower-than-expected quarterly sales growth on Friday, hurt by further weakness in its Scholl footcare business.

Reckitt Benckiser CEO gets second pay cut in two years

LONDON Reckitt Benckiser's chief executive Rakesh Kapoor got an 18 percent pay cut in 2017, his second in two years, due to a halving of his long-term incentive benefits, after a year of underperformance at the British consumer goods company.

Reckitt Benckiser CEO gets second pay cut in two years

LONDON, March 28 Reckitt Benckiser's chief executive Rakesh Kapoor got an 18 percent pay cut in 2017, his second in two years, due to a halving of his long-term incentive benefits, after a year of underperformance at the British consumer goods company.

GSK advances in Pfizer consumer health auction as Reckitt quits

NEW YORK/LONDON GlaxoSmithKline has pulled ahead in a race to buy Pfizer's consumer healthcare business, which the U.S. drugmaker believes could be worth as much as $20 billion, after its main rival Reckitt Benckiser quit the auction.

UPDATE 6-GSK advances in Pfizer consumer health auction as Reckitt quits

* Reckitt shares up more than 5 percent, GSK down 1 percent (Updates with GSK submitting bid)

Back to the drawing board for Reckitt after dropping Pfizer bid

LONDON Reckitt Benckiser's decision to drop its pursuit of Pfizer's consumer health assets leaves it with a tough job to restore growth to its flat-lining business.

Select another date: